99 related articles for article (PubMed ID: 30327581)
21. The potential role of T-cells and their interaction with antigen-presenting cells in mediating immunosuppression following trauma-hemorrhage.
Walz CR; Zedler S; Schneider CP; Albertsmeier M; Loehe F; Bruns CJ; Faist E; Chaudry IH; Angele MK
Innate Immun; 2009 Aug; 15(4):233-41. PubMed ID: 19586998
[TBL] [Abstract][Full Text] [Related]
22. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Schultze JL; Michalak S; Seamon MJ; Dranoff G; Jung K; Daley J; Delgado JC; Gribben JG; Nadler LM
J Clin Invest; 1997 Dec; 100(11):2757-65. PubMed ID: 9389740
[TBL] [Abstract][Full Text] [Related]
23. Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells.
Zhang R; Liu TY; Senju S; Haruta M; Hirosawa N; Suzuki M; Tatsumi M; Ueda N; Maki H; Nakatsuka R; Matsuoka Y; Sasaki Y; Tsuzuki S; Nakanishi H; Araki R; Abe M; Akatsuka Y; Sakamoto Y; Sonoda Y; Nishimura Y; Kuzushima K; Uemura Y
Cancer Immunol Res; 2015 Jun; 3(6):668-77. PubMed ID: 25672396
[TBL] [Abstract][Full Text] [Related]
24. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.
Mortarini R; Anichini A; Di Nicola M; Siena S; Bregni M; Belli F; Molla A; Gianni AM; Parmiani G
Cancer Res; 1997 Dec; 57(24):5534-41. PubMed ID: 9407964
[TBL] [Abstract][Full Text] [Related]
25. Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors.
Sheil JM; Frankenberry MA; Schell TD; Brundage KM; Barnett JB
Environ Health Perspect; 2006 Jul; 114(7):1059-64. PubMed ID: 16835059
[TBL] [Abstract][Full Text] [Related]
26. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo.
Agadjanyan MG; Kim JJ; Trivedi N; Wilson DM; Monzavi-Karbassi B; Morrison LD; Nottingham LK; Dentchev T; Tsai A; Dang K; Chalian AA; Maldonado MA; Williams WV; Weiner DB
J Immunol; 1999 Mar; 162(6):3417-27. PubMed ID: 10092797
[TBL] [Abstract][Full Text] [Related]
27. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses.
De Bruijn ML; Nieland JD; Schumacher TN; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1992 Nov; 22(11):3013-20. PubMed ID: 1425925
[TBL] [Abstract][Full Text] [Related]
29. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.
Bhardwaj N; Bender A; Gonzalez N; Bui LK; Garrett MC; Steinman RM
J Clin Invest; 1994 Aug; 94(2):797-807. PubMed ID: 8040335
[TBL] [Abstract][Full Text] [Related]
30. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
[TBL] [Abstract][Full Text] [Related]
31. Antigen-presenting human T cells and antigen-presenting B cells induce a similar cytokine profile in specific T cell clones.
Wyss-Coray T; Gallati H; Pracht I; Limat A; Mauri D; Frutig K; Pichler WJ
Eur J Immunol; 1993 Dec; 23(12):3350-7. PubMed ID: 7504995
[TBL] [Abstract][Full Text] [Related]
32. Effect of B7-2 and CD40 signals from activated antigen-presenting cells on the ability of zwitterionic polysaccharides to induce T-Cell stimulation.
Stephen TL; Niemeyer M; Tzianabos AO; Kroenke M; Kasper DL; Kalka-Moll WM
Infect Immun; 2005 Apr; 73(4):2184-9. PubMed ID: 15784561
[TBL] [Abstract][Full Text] [Related]
33. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
[TBL] [Abstract][Full Text] [Related]
34. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
35. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
36. A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity.
Hayashi A; Wakita H; Yoshikawa T; Nakanishi T; Tsutsumi Y; Mayumi T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
J Control Release; 2007 Jan; 117(1):11-9. PubMed ID: 17126444
[TBL] [Abstract][Full Text] [Related]
37. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
Chung SW; Cohen EP; Kim TS
Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
[TBL] [Abstract][Full Text] [Related]
38. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
39. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells.
Daftarian P; Kaifer AE; Li W; Blomberg BB; Frasca D; Roth F; Chowdhury R; Berg EA; Fishman JB; Al Sayegh HA; Blackwelder P; Inverardi L; Perez VL; Lemmon V; Serafini P
Cancer Res; 2011 Dec; 71(24):7452-62. PubMed ID: 21987727
[TBL] [Abstract][Full Text] [Related]
40. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
